Viral dynamic modelling of Hepatitis C and resistance-associated variants in haemophiliacs.

ABSTRACT:

Aim

Chronic hepatitis C virus (HCV) infection is an important source of morbidity and mortality among haemophiliacs. Limited data are available regarding treatment intervention using direct-acting antivirals (DAAs) and theoretical concerns regarding accumulation of drug-associated resistance variants (RAVs) remain. We conducted a pilot study of treatment with telaprevir/pegylated interferon-alfa/ribavirin to evaluate treatment response and the role of lead-in DAA therapy on mutational selection of resistance variants.

Methods

Ultra-deep sequence analysis was performed at baseline, 48 hours and 168 hours after treatment initiation.

Results

No dominant RAVs were identified at baseline, but low-level RAVs were noted at baseline in all subjects. Viral dynamic models were

SUBMITTER: Sherman KE 

PROVIDER: S-EPMC4958555 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature